Form 4: Cognition Therapeutics Director Acquires Shares and Options

Director Peggy Wallace acquired 8,500 shares of common stock and options in Cognition Therapeutics on June 7, 2024.

Summary

• On June 7, 2024, Peggy Wallace, a director of Cognition Therapeutics, acquired 8,500 shares of common stock represented by restricted stock units (RSUs) and options to purchase 8,500 shares.
• The RSUs and options vest on the earlier of June 7, 2025, or the date of the Issuer's next annual meeting of stockholders, contingent upon continuous service as a director.
• The exercise price for the options is $1.95.
• Following the transaction, Wallace directly owns 52,461 shares of Cognition Therapeutics.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares and options suggests confidence in the company's prospects, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and options is contingent upon the director's continuous service, aligning their interests with the company's long-term performance.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's valuation and future performance. This Form 4 filing is a routine disclosure required by the SEC.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment.

Key Dates